Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 1 3Phase 2/3 2Phase 1/2 2

Status

Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Non-Small-Cell Lung 145Breast Neoplasms 113Prostatic Neoplasms 58Multiple Myeloma 57Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 42Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 34Leukemia, Lymphocytic, Chronic, B-Cell 33Colorectal Neoplasms 32Carcinoma, Renal Cell 26Recurrence 25Leukemia, Myeloid, Acute 25Urinary Bladder Neoplasms 23Myasthenia Gravis 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 21Lymphoma, Large B-Cell, Diffuse 21Squamous Cell Carcinoma of Head and Neck 20Small Cell Lung Carcinoma 20Lymphoma, Follicular 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 17Melanoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Gemcitabine 5Cisplatin 5pembrolizumab 3durvalumab 2zanidatamab 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Folfox protocol 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Gallbladder Neoplasms × 90 days × Clear all
NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
158 enrolled 19 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡